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ABSTRACT   Lung cancer is the leading cause of cancer-related death. Surgery has been 
playing a pivotal role in the treatments with curative intent for non-small cell lung cancer 
(NSCLC). However, the outcome after surgery alone remains unsatisfactory. During the last 
two decades, several attempts have been made to improve the postoperative outcome. Meta-
analysis demonstrated that adjuvant cisplatin-based chemotherapy achieved 4-5% of benefit 
in the 5-year survival as compared to surgery alone. Preoperative induction chemotherapy 
also yielded a 5% improvement of the 5-year survival rate, showing a similar efficacy with 
adjuvant chemotherapy. Induction chemoradiotherapy enhanced local control, whereas it 
was not associated with any survival benefit. Recently, the development of new drugs, such 
as tyrosine kinase inhibitors and immune checkpoint inhibitors, represents a major treatment 
advance for patients with lung cancer. Several attempts have been made to apply these drugs 
to perioperative treatments.
   In this review, we sought to summarize the developments of perioperative therapy in the 
treatments of NSCLC, and discuss the future perspectives.
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〈Review〉
the postoperative survival rates of patients with 
NSCLC had improved over the last few decades, 
with the current 5-year survival rate of 82.0% in 
clinical stage IA patients and 63.4% in clinical stage 
IB patients１）. These improvements are thought 
to be due to improvements in the treatments and 
perioperative management techniques, and stage 
INTRODUCTION
   Lung cancer remains the leading cause of cancer-
related death worldwide. In Japan, more than 73000 
people died of lung cancer in 2016. Non-small cell 
lung cancer (NSCLC) accounts for about 85% of 
all cases of lung cancer. A survey conducted by 
the Japanese Lung Cancer Registry showed that 
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a significant improvement in the postoperative 
survival associated with cisplatin-based adjuvant 
chemotherapy as compared to surgery alone６）. In 
this study, patients with pathological stage I to III 
NSCLC were randomly assigned to the cisplatin-
based adjuvant chemotherapy or surgery alone 
group. The treatment offered a 4% benefit in the 
5-year survival rate (44.5% in the chemotherapy 
group vs. 40.4% in the control, surgery-alone group) 
and the HR was 0.86 (95% CI, 0.76 to 0.98, p < 
0.03). 
   After this milestone trial, results of important 
studies were published in succession (Table 1). 
The JBR.10 trial compared the benefit of adjuvant 
vinorelbine plus cisplatin therapy as compared to 
surgery alone in patients with stage IB or stage II 
NSCLC７）. The overall survival was significantly 
bet ter  in  the group that  received adjuvant 
chemotherapy, with a 15% advantage in the 5-year 
survival rate (69% vs. 54%, p = 0.03). The Adjuvant 
Nabelbine International Trialist Association 
(ANITA) study compared the benefit of adjuvant 
vinorelbine plus cisplatin therapy over observation 
alone in patients with completely resected stage IB-
IIIA NSCLC８）. The median survival time was 65.7 
months in the adjuvant chemotherapy group and 
43.7 months in the observation alone group, with 
migration with radiological advances. However, 
the postoperative outcomes in patients with locally 
advanced NSCLC still remains unsatisfactory, with 
a current 5-year survival rate of 43.3% in clinical 
stage IIIA patients１）. Recurrence in distant organs is 
reported as the most common pattern of recurrence 
after complete resection in patients with locally 
advanced NSCLC２－４）. During the last two decades, 
several attempts have been made to improve the 
postoperative outcomes in patients with NSCLC. In 
this review, we present an overview of the current 
status and future perspectives of the post and 
preoperative treatments for NSCLC. 
Adjuvant Chemotherapy for Completely Resected 
Locally Advanced NSCLC
   In 1995, the Non-small Cell Lung Cancer 
Collaborative Group reported the efficacy of 
adjuvant chemotherapy after complete resection in 
patients with NSCLC５）. This meta-analysis, which 
included 14 trials and 4357 patients, demonstrated 
that cisplatin-based adjuvant chemotherapy yielded 
a 5% survival benefit at 5 years, although the 
difference was not significant, with a hazard ratio 
(HR) of 0.87 (P = 0.08). 
   In 2004,  the International Adjuvant Lung 
Cancer Trial (IALT) showed, for the first time, 
Table 1. Results of phase III trials of adjuvant chemotherapy
Study Stage No. of patients Adjuvant intervention Outcome p
ALPI９）(2003) I – IIIA 1209 MVPobservation
Median Survival 55.2mo
 48mo 0.589
Big Lung Trial10）(2004) I – III 381 CDDP-basedobservation
Median Survival 33.9mo
 32.6mo 0.9
IALT６）(2004) I – III 1867 CDDP-basedobservation
5-year OS 44.5%
 40.4% < 0.03
Kato, et al.17）(2004) I (Ad)  999 UFTobservation
5-year OS 88%
 85% 0.047
JBR.10７）(2005) IB – II 482 CDDP+VNRobservation 
5-year OS 69%
 54% 0.03
ANITA８）(2006) IB – IIIA 840 CDDP+VNR observation
Median Survival 65.7mo
 43.7mo 0.017
CALGB963321）(2008) IB  344 CBDCA+PACobservation
Median Survival 98mo
 78mo 0.125
Abbreviations: Ad, adenocarcinoma; MVP, mitomycin + vindesin + cisplatin; CDDP, cisplatin; UFT, uracil-tegafur; VNR, 
vinorelbine; CBCDA, carboplatin; PAC, paclitaxel; OS, overall survival
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a HR of 0.80 (95% CI, 0.66 to 0.96, p = 0.017); 
adjuvant chemotherapy offered a survival benefit 
of 8.6% at 5 years. On the other hand, the Adjuvant 
Lung Cancer Project Italy (ALPI) study９） and the 
Big Lung Trial10） failed to demonstrate any benefit 
of adjuvant chemotherapy after surgical resection in 
patients with NSCLC. 
   Following these conflicting results, two meta-
analyses were conducted. The Lung Adjuvant 
Cisplatin Evaluation (LACE) analysis, which 
analyzed the results of the IALT, JBR.10, ANITA, 
ALPI, and Big Lung Trial, revealed a 5.4% benefit 
in the 5-year survival rate of adjuvant cisplatin-
based chemotherapy, with a HR of 0.89 (95% CI, 
0.82 to 0.96, p = 0.005)11）. The NSCLC Meta-
analyses Collaborative Group conducted a meta-
analysis of the results of 34 trials including 8447 
patients to compare the survival outcomes of 
surgery plus chemotherapy with those of surgery 
alone12）. The results showed a 4% benefit in the 
5-year survival of surgery plus chemotherapy as 
compared to surgery alone, with a HR of 0.86 (95% 
CI, 0.81 to 0.92, p < 0.0001). The results of these 
meta-analyses established the efficacy of adjuvant 
chemotherapy following complete resection in 
patients with NSCLC, with a 5-year survival benefit 
of 4-5%, which was similar to the result of the 
Non-small Cell Lung Cancer Collaborative Group 
published in 1995.
   Some studies have also reported the long-term 
effects of adjuvant chemotherapy. In the IALT study, 
cisplatin-based adjuvant chemotherapy yielded a 
survival benefit over a median follow-up of 7.5 
years, but the difference in the outcomes was not 
statistically significant (HR 0.91: 95% CI, 0.81 to 
1.02, p = 0.10)13）. On the other hand, in JBR.10, a 
significant survival benefit of adjuvant vinorelbine 
plus cisplatin continued to be observed after a 
median follow-up of 9.3 years (HR 0.78: 95% CI, 
0.61 to 0.99, p = 0.04)14）.
   As for the chemotherapy regimen, the LACE 
study demonstrated that cisplatin plus vinorelbine 
was marginally more effective than other drug 
regimens. A search for the optimal regimen is 
still ongoing. The E1505 trial was conducted to 
investigate the effect of addition of bevacizumab 
to cisplatin-based chemotherapy15）. A total of 1501 
patients with completely resected stage IB (tumor 
larger than 4 cm) -stage IIIA NSCLC were assigned 
to the cisplatin-based chemotherapy group or the 
cisplatin-based chemotherapy plus bevacizumab 
group. The choice of chemotherapeutic agents 
administered in combination with cisplatin was left 
to the investigators’ choice (vinorelbine, docetaxel, 
gemcitabine, or pemetrexed). The results showed 
that addition of bevacizumab had no effect of 
improving the overall survival (HR 0.99: 95% 
CI, 0.82 to 1.19, p = 0.90). The JIPANG study is 
an ongoing study being conducted to evaluate the 
efficacy of pemetrexed plus cisplatin, as compared 
to that of vinorelbine plus cisplatin, in patients with 
completely resected stage II-IIIA non-squamous 
NSCLC16）. A total of 800 patients were enrolled and 
are now being followed-up. 
   In conclusion, although adjuvant chemotherapy 
for completely resected locally advanced NSCLC 
appears to be beneficial, the survival benefit is 
not sufficient and the long-term efficacy remains 
controversial. Furthermore, the ideal chemotherapy 
regimen is also still under investigation.
Adjuvant Chemotherapy for Early-Stage NSCLC
   In contrast to the case for locally advanced 
NSCLC, the efficacy of adjuvant chemotherapy for 
completely resected T1N0M0 NSCLC still remains 
under debate. 
   In 2004, postoperative adjuvant chemotherapy 
with uracil-tegafur was reported to offer significant 
survival benefit for patients with pathological stage 
I lung adenocarcinoma17）. In this study, 999 patients 
with stage I (T1N0M0 or T2N0M0) adenocarcinoma 
were randomly assigned to oral uracil-tegafur 
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therapy given twice daily for two years, or 
observation alone. The 5-year survival rate was 
significantly better in the uracil-tegafur group (HR 
0.71: 95% CI, 0.52 to 0.98, p = 0.04), with the 3% 
benefit in the 5-year survival rate (88% in the uracil-
tegafur group vs. 85% in the observation alone 
arm). However, a subgroup analysis revealed that 
the survival benefit was seen only in patients with 
T2 disease (tumors larger than 3 cm in diameter) 
(HR 0.48: 95% CI, 0.29 to 0.81, p = 0.005), with no 
difference seen in those with T1 disease (HR 0.97: 
95% CI, 0.64 to 1.46, p = 0.87). A meta-analysis 
of 6 studies including 2003 patients revealed that 
adjuvant uracil-tegafur therapy was associated with 
a significantly improved 5-year overall survival rate 
as compared to surgery alone (HR 0.74: 95% CI, 
0.61 to 0.88, p = 0.001)18）. The 5-year survival rate 
in the uracil-tegafur group was 4.6% higher than 
that in the observation group (81.8% vs. 77.2%). 
Notably, a subset analysis in this meta-analysis 
demonstrated the survival benefit of uracil-tegafur 
therapy even in patients with T1 disease (HR 
0.73: 95% CI, 0.56 to 0.93). As for the influence 
of the histologic type, the outcome of uracil-
tegafur therapy was also favorable in patients with 
squamous cell carcinoma (HR 0.82: 95% CI, 0.57 to 
1.19). Another meta-analysis of the same 6 studies 
showed that uracil-tegafur therapy significantly 
improved the postoperative survival in patients with 
T1 tumors larger than 2 cm in diameter (HR 0.62: 
95% CI, 0.42 to 0.90, p = 0.011), but not in patients 
with T1 tumors smaller than 2 cm in diameter (HR 
0.84: 95% CI, 0.58 to 1.23, p = 0.37)19）. Based on 
these lines of evidence, postoperative adjuvant 
uracil-tegafur therapy is recommended in Japan 
for patients with T1 tumors larger than 2 cm in 
diameter. Recently, the Japan Clinical Oncology 
Group (JCOG) conducted a trial comparing uracil-
tegafur with S-1, an oral agent consisting of tegafur 
and gimeracil, for patients with stage I NSCLC. 
Enrollment has been completed, and the results are 
awaited. 
   As for platinum-based chemotherapy, Cancer 
and Leukemia Group B (CALGB) Protocol 9633 
was a study conducted to investigate the efficacy 
of paclitaxel plus carboplatin as postoperative 
adjuvant chemotherapy for patients with NSCLC20）. 
A total of 344 patients with T2N0M0 Stage IB 
NSCLC were randomized to adjuvant paclitaxel 
plus carboplatin therapy, or observation alone. The 
preliminary result, obtained after a median follow-
up of 34 months, showed that the 4-year overall 
survival in the paclitaxel plus carboplatin group was 
significantly better than that in the observation alone 
group (71% vs. 59%)20）. However, the survival 
difference was no longer statistically significant 
after a long-term median follow-up period of 
74 months (HR 0.83: 95% CI, 0.64 to 1.08, p = 
0.12)21）; on the other hand, an exploratory analysis 
in this study demonstrated that the outcome in the 
chemotherapy group was more favorable in patients 
with tumors ≧ 4 cm in diameter (HR 0.69: 95% CI, 
0.48 to 0.99, p = 0.043). 
   JBR.10 and ANITA were also trials including 
patients with stage IB disease. In JBR.10, adjuvant 
vinorelbine plus cisplatin showed a significant 
survival benefit in patients with stage II NSCLC, 
whereas no benefit was noted in patients with stage 
IB disease (HR 1.03: 95% CI, 0.70 to 1.52, p = 
0.87)14）. Even in stage IB patients with tumors  ≧ 4 
cm in diameter, no significant benefit was observed 
in the chemotherapy group (HR 0.66: 95% CI, 
0.39 to 1.14, p = 0.133). In the ANITA study also, 
which included patients with stage IB-IIIA disease, 
a subset analysis revealed the absence of any 
survival benefit of chemotherapy in patients with 
stage IB disease (HR 1.10: 95% CI, 0.76 to 1.57)８）. 
Considering these results, it could be concluded 
that the efficacy of postoperative adjuvant 
chemotherapy with a platinum-based regimen for 
patients with stage IB disease remains unconfirmed 
yet. Several studies have suggested that some 
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clinicopathological factors, including the tumor 
size21）, tumor histology22）, presence/absence of 
lymphovascular invasion23，24）, and presence/absence 
of pleural invasion25）, could be useful for selecting 
suitable candidates for postoperative adjuvant 
chemotherapy among patients with resected early 
NSCLC. However, further study is warranted to 
confirm these results. 
Customized Chemotherapy with Biomarkers
   Although the efficacy of adjuvant chemotherapy 
for NSCLC has been confirmed, the survival benefit 
remains far from satisfactory. In 2006, the IALT 
Bio study suggested that the excision repair cross-
complementation group 1 (ERCC1) could be a 
predictive biomarker to select suitable candidates 
for cisplatin-based chemotherapy26）. ERCC1 is 
thought to be one of the nucleotide excision repair 
factors, which remove cisplatin-induced DNA 
adducts, inducing resistance to cisplatin-based 
chemotherapy. In this study, paraffin-embedded 
tumor samples of 761 patients enrolled in the IALT 
were subjected to immunostaining for ERCC1 
protein. While the overall survival was significantly 
better in the chemotherapy group than in the surgery 
alone group among the patients with ERCC1-
negative tumors, (HR 0.65: 95% CI, 0.50 to 0.86, p 
= 0.002), no such difference in the survival between 
the two groups was observed among the patients 
with ERCC1-positive tumors (HR 1.14: 95% 
CI, 0.84 to 1.55, p = 0.40). This study concluded 
that patients with ERCC1-negative tumors were 
probably better candidates for cisplatin-based 
adjuvant chemotherapy than those with ERCC1-
positive tumors. 
   Since then, several studies have attempted 
to confirm this result. However, the results are 
conflicting27－31）. As possible reasons for this 
inconsistency, Friboulet et al. pointed out that the 
ERCC1 gene generates four isoforms, and that 
the available antibodies used for the detection of 
ERCC1 expression cannot precisely identify the 
functional ERCC1 isoform32）. A meta-analysis 
suggested that high ERCC1 expression might be 
adversely related to the efficacy of platinum-based 
chemotherapy33）, but definitive evidence is lacking. 
The International Tailored Chemotherapy Adjuvant 
(ITACA) trial was a randomized controlled study 
performed to validate the efficacy of biomarker-
based customized adjuvant chemotherapy34）. In 
the experimental arm of this study, chemotherapy 
regimens were determined according to the ERCC1 
and thymidylate synthase (TS) messenger RNA 
expression levels. Patient enrolment was completed 
in 2014, and the final results of the trial are awaited. 
   Other biomarkers which have been expected to 
be useful predictors of the responses to certain 
chemotherapies are RRM1 for gemcitabine35，36） and 
class III β-tubulin for the taxanes37，38）. However, 
the results are again conflicting. At present, 
customized chemotherapy according to predictive 
biomarkers is not yet possible in clinical practice. 
Postoperative Radiotherapy
   In 1998, the PORT Meta-analysis Trialists Group 
demonstrated that postoperative radiotherapy after 
complete resection was associated with an adverse 
effect on the survival in patients with NSCLC (HR 
1.21: 95% CI, 1.08 to 1.34), based on the analyses 
of 2128 individual patient data from 9 randomized 
studies39）. According to this analysis, for patients 
with N0-1 disease, postoperative radiotherapy was 
associated with a worsened survival, as compared 
to surgery alone. On the other hand, the survival 
was equivalent between the two groups in patients 
with N2 disease. At the time when this analysis 
was reported, the results were criticized, because it 
included studies that employed outdated radiation 
techniques or inadequate radiation regimens. As for 
pN2 disease, Douillard et al. reported the improved 
survival in the patients who received PORT 
compared with that in the patients who did not in 
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the retrospective study of ANITA trial40）.
   In 2016, the meta-analysis was updated and was 
conducted based on 14 randomized controlled 
trials that used the latest radiological techniques, 
including 2343 patients41）. The results again 
showed a significant adverse effect of postoperative 
radiotherapy on the overall survival (HR 1.18: 
95% CI, 1.07 to 1.31, p = 0.001). Locoregional 
recurrence-free survival was also significantly 
inferior in the adjuvant radiotherapy group (HR 
1.12: 95% CI, 1.01 to 1.24, p = 0.03). No difference 
was noted depending on the nodal status. 
   These results suggested that postoperative 
radiotherapy after complete resection had a 
detrimental effect on the survival in patients with 
NSCLC. However, for N2 disease, the ongoing 
Lung ART trial, which is a randomized study 
targeted at patients with N2 disease, is expected to 
clarify the effect of adjuvant radiotherapy. 
Induction Chemotherapy
   During the 1990s, epoch-making results of three 
phase III trials were reported, which suggested 
the effectiveness of induction chemotherapy 
for NSCLC. In 1992 ,  Pass et al .  reported a 
more favorable median survival associated with 
preoperative chemotherapy with etoposide/cisplatin 
as compared to that with surgery alone in 27 patients 
with stage IIIA NSCLC (p = 0.095)42）. Rosell et 
al. compared preoperative chemotherapy using 
mitomycin/ifosfamide/cisplatin with surgery alone 
in 60 patients with stage IIIA NSCLC. Each of the 
treatment arms included postoperative radiation. 
The median survival was 26 months in the induction 
arm and 8 months in the non-induction arm (p 
< 0.001)43）. The study of Roth et al., in which 
preoperative cyclophosphamide/etoposide/cisplatin 
therapy was compared with surgery alone in 60 
patients with stage IIIA NSCLC, the median survival 
was 64 months in the induction arm vs. 8 months in 
the surgery alone arm (p < 0.008)44）. These results 
indicate the efficacy of induction chemotherapy for 
locally advanced NSCLC, however, some concerns 
were pointed out, including the small sample size 
and the poorer than expected outcome in the surgery 
alone group. 
   Thereafter, several randomized trials have been 
conducted. In 2014, the NSCLC Meta-analysis 
Collaborative Group conducted a systematic review 
and meta-analysis of individual participant data 
of 15 randomized trials including 2385 patients45）. 
The results revealed a significant survival benefit 
of preoperative chemotherapy as compared to 
surgery alone (HR 0.87: 95% CI, 0.78 to 0.96, p = 
0.007). There was a 5% improvement of the 5-year 
survival rate, with a 13% reduction in the relative 
risk of death. Notably, this benefit of 5% was seen 
from stage IB through stage III. The chemotherapy 
regimen, whether cisplatin-based or carboplatin-
based, has no influence on the results. 
   Based on these results, induction chemotherapy 
has come to be recognized as one of the treatment 
strategies for locally advanced NSCLC. 
I n d u c t i o n  C h e m o t h e r a p y  v s .  A d j u v a n t 
Chemotherapy
   The Neoadjuvant versus Adjuvant Taxol/Carbo 
Hope (NATCH) trial was the first randomized 
controlled trial to directly compare the benefits of 
induction chemotherapy with those of adjuvant 
chemotherapy46）. A total of 624 patients with 
stage IA (tumor at least 2 cm in diameter), IB, II, 
or IIIA (T3N1) NSCLC were randomly assigned 
to the surgery alone group, the adjuvant therapy 
group, or the induction chemotherapy group. The 
chemotherapy regimen used in the adjuvant and 
induction therapy groups were 3 cycles of paclitaxel 
and carboplatin. The results showed that there were 
no significant differences in the 5-year overall 
survival rates among the three groups, with the rates 
being 46.6%, 45.5%, and 44.0% in the induction, 
adjuvant, and surgery alone arms, respectively. 
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These unexpected results were likely attributable to 
the fact that more than 70% of the enrolled patients 
had stage IA disease. In terms of the tolerability, the 
chemotherapy was better tolerated in the induction 
therapy arm. A larger number of patients allocated to 
the induction arm underwent planned chemotherapy 
as compared to those in the adjuvant arm (97% vs. 
66.2%, p < 0.0001).
   A systematic review of 32 randomized trials 
demonstrated that the relative hazards of the 
adjuvant chemotherapy as compared to induction 
therapy was 0.99 (95% CI, 0.81 to 1.21, p = 0.91)47）. 
This review had the limitation that the study was 
made with the indirect comparison including the 
relatively small studies. However, the results were 
convincing, considering that the hazard ratios of 
adjuvant chemotherapy and induction chemotherapy 
were similar (0.86-0.89) in previous individual 
meta-analyses comparing these treatments with 
surgery alone12，45）. 
Induction Chemoradiotherapy
   R e s p o n d i n g  t o  t h e  p o s i t i v e  r e s u l t s  o f 
induction chemotherapy, the effect of induction 
chemoradiotherapy to enhance the local control has 
been investigated. In 1995, Albain et al. studied 
the feasibility of concurrent chemoradiotherapy 
for locally advanced NSCLC48）. In this phase II 
study, 126 patients with stage IIIA and IIIB NSCLC 
were treated with two cycles of cisplatin/etoposide 
and concurrent radiotherapy at the dose of 45 Gy, 
followed by surgery. The response rate to induction 
therapy was 59%, and 107 of the 126 patients 
became suitable candidates for surgical treatment. 
The 3-year survival rates were 27% in the patients 
with stage IIIA disease and 24% in those with stage 
IIIB disease. 
   However, none of the subsequent randomized 
controlled trials have been able to confirm 
the additional survival benefit over induction 
chemotherapy to date. Thomas et al. conducted 
a study to compare preoperative concurrent 
chemoradiotherapy (45 Gy) with preoperative 
chemotherapy alone in patients with stage III 
NSCLC49）. The results showed more favorable 
mediastinal downstaging and pathological response 
in the chemoradiotherapy group, but the median 
progression-free survivals were equivalent (HR 
0.99: 95% CI, 0.81 to 1.19, p = 0.87). Similarly, 
Pless et al. conducted a randomized controlled 
trial to compare preoperative chemoradiotherapy 
(cisplatin plus docetaxel and total radiation dose 44 
Gy) and preoperative chemotherapy alone50）. The 
results again showed more favorable response rates 
in the chemoradiotherapy group, whereas the median 
event-free survivals were similar (HR 1.1: 95% CI, 
0.8 to 1.4, p = 0.67). In 2016, a meta-analysis of 4 
randomized controlled studies revealed that tumor 
downstaging (p = 0.01) and local control (p = 0.002) 
were better in the chemoradiotherapy, but that there 
was no benefit in the 5-year overall survival (HR 
0.89: 95% CI, 0.68 to 1.19, p = 0.44) or progression-
free survival (HR 0.72: 95% CI, 0.60 to 0.88, p 
= 0.26)51）. Considering these results, it could be 
concluded that enhanced local control by intensive 
preoperative concurrent chemoradiotherapy is not 
associated with any survival benefit in patients with 
locally advanced NSCLC.
   On the other hand, for patients with superior sulcus 
tumor (T3-4N0-1), preoperative chemoradiotherapy 
followed by surgery is considered to be the standard 
treatment. This strategy is based on the results of 
two phase II studies. The Southwest Oncology 
Group Trial 9416 (SWOG9416/Intergroup Trial 
0160) demonstrated that after 2 cycles of cisplatin/
etoposide and radiation therapy (45 Gy), 76% 
of patients could undergo complete resection, 
and the 5-year survival rate was 44%52）. In the 
Japan Clinical Oncology Group trial 9806, after 
MVP and radiation therapy (45 Gy), the complete 
resection rate was 68%, and the 5-year survival 
rate was 56%53）. Due to the rarity of this disease, 
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randomized controlled trials seem impossible, 
however, considering the similarity of these results 
and the superiority of the results as compared to the 
historical data, induction chemoradiotherapy is now 
strongly recommended for patients with superior 
sulcus NSCLC. 
Should cN2-NSCLC be resected?
   Although the significance of perioperative 
therapies for locally advanced NSCLC are 
described in the above sections, most cases with 
infiltrative N2-NSCLC are treated by definitive 
chemoradiotherapy without surgical resection. 
The INT0139 study was designed to clarify the 
significance of radical surgery after concurrent 
chemoradiotherapy for patients with Stage IIIA 
(pN2) NSCLC54）. In this study, 396 patients were 
randomly assigned to definitive chemoradiotherapy, 
which included 2 cycles of cisplatin/etoposide and 
concurrent radiotherapy at the total dose of 60 Gy, 
or to 2 cycles of chemotherapy plus radiation at the 
total dose of 45 Gy followed by surgical resection. 
The results showed that the median overall survivals 
in the two groups were 23.6 months and 22.2 
months, respectively, with no significant difference 
between the two treatment arms (HR 0.87: 95% 
CI, 0.70 to 1.10, p = 0.24). On the other hand, the 
progression-free survival was significantly better 
in the definitive chemoradiotherapy group (12.8 
months vs. 10.5 months, HR 0.77: 95% CI, 0.62 
to 0.96, p = 0.017). These results suggest that the 
surgical resection after chemoradiotherapy has little 
impact on the prognosis in patients with N2 disease. 
   On the other hand, the PACIFIC study was 
a randomized controlled study conducted to 
compare durvalumab, a monoclonal antibody 
to programmed death ligand 1 (PD-L1), with 
placebo as consolidation therapy after platinum-
based chemoradiotherapy for unresectable stage 
III NSCLC55）. Of the 713 patients who underwent 
randomization, 348 patients (52.9%) had stage IIIA. 
The median progression-free survival was 16.8 
months in the durvalumab arm vs. 5.6 months in 
the placebo arm (HR 0.52: 95% CI, 0.42 to 0.65, p 
< 0.001). The 24-month overall survival rate was 
also significantly superior in the durvalumab arm 
as compared to that in the placebo arm (66.3% 
vs. 55.6%, HR 0.68: 95% CI, 0.47 to 0.997, p = 
0.0025)56）. This survival benefit was observed 
across all the prespecified subgroups. 
   Considering the results of these studies, the 
standard treatment, to date, for locally advanced 
NSCLC, including infiltrative N2 disease, is thought 
to be induction platinum-based chemoradiotherapy 
followed by consolidation therapy with durvalumab; 
surgical resection after induction chemoradiotherapy 
may be attempted in selected candidates. 
FUTURE PERSPECTIVES
1) EGFR-TKIs
   Epidermal growth factor receptor (EGFR) 
-tyrosine kinase inhibitors (TKIs) have been 
the standard first-line treatment for advanced 
NSCLC patients harboring EGFR mutations. 
It is not surprising that EGFR-TKIs have been 
expected to prolong the survival of patients with 
resected NSCLC. Several randomized trials have 
been conducted to date to clarify the efficacy of 
postoperative EGFR-TKI therapy as adjuvant 
therapy. 
   BR19 was a phase III study comparing gefitinib 
with placebo as postoperative adjuvant therapy 
after complete resection in patients with NSCLC57）. 
A total of 503 patients with stage IB, II, or IIIA 
NSCLC were randomly assigned to the two arms. 
The results revealed no significant difference in the 
overall survival (HR 1.24: 95% CI, 0.94 to 1.64, 
p = 0.14) or progression-free survival (HR 1.22: 
95% CI, 0.93 to 1.61, p = 0.15) between the two 
arms. The RADIANT study compared erlotinib 
with placebo as postoperative adjuvant therapy for 
patients with stage IB- IIIA NSCLC58）. The disease-
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free survival, the primary endpoint of this study, was 
comparable between the two groups (50.5 months 
for erlotinib vs. 48.2 months for placebo, HR 0.90: 
95% CI, 0.74 to 1.10, p = 0.324). However, among 
the patients with EGFR-mutant NSCLC, the median 
disease-free survival was more favorable in the 
erlotinib group (46.4 months vs. 28.5 months). 
   The CTONG1104 study59） and EVAN study60） 
compared EGFR-TKI therapy with chemotherapy as 
postoperative adjuvant therapy. In the CTONG1104 
study, gefitinib was compared with cisplatin plus 
vinorelbine for patients with stage II-IIIA EGFR-
mutant NSCLC. The disease-free survival was 
significantly better in the gefitinib group (28.7 
months vs. 18.0 months, HR 0.60: 95% CI, 0.42 
to 0.87, p = 0.0054). The EVAN study was a 
randomized phase II study comparing erlotinib with 
cisplatin plus vinorelbine for patients with stage IIIA 
EGFR-mutant NSCLC. The trial revealed that the 
2-year disease-free survival rate was significantly 
better in the erlotinib group (81.4% vs. 44.6%, p = 
0.0054). 
   On the other hand, CTONG1103 study was a 
randomized phase II study comparing erlotinib with 
gemcitabine plus cisplatin as preoperative therapy 
for N2 EGFR-mutant NSCLC61）. The primary 
endpoint was the response rate. The results showed 
that the response rate was superior in the erlotinib 
arm (54.1% vs. 34.3%, p = 0.092), but the difference 
was not significant, meaning the primary endpoint 
was not met. However, the progression-free survival 
was significantly better in the erlotinib arm (HR 
0.39: 95% CI, 0.23 to 0.67, p < 0.001).
   The results of these studies indicate that 
perioperative EGFR-TKIs prolong the disease-free 
survival in patients with EGFR-mutant NSCLC. 
However, the benefit on the overall survival still 
remains unknown. At present, the ADAURA trial 
is ongoing to evaluate the efficacy of osimertinib, a 
third-generation EGFR inhibitor, as postoperative 
adjuvant therapy in patients with EGFR-mutant 
NSCLC62）. Osimertinib has already been established 
to be superior to the first-generation EGFR-TKIs, 
gefitinib and erlotinib63）; therefore, the results of the 
ADAURA trial are eagerly awaited.
2) Immune Checkpoint Inhibitors
   The recent development of immune checkpoint 
inhibitors (ICI), which block the immune inhibitory 
pathway of PD-1/PD-L1, represents a major 
treatment advance for patients with lung cancer. 
Since these drugs have become key drugs for the 
treatment of advanced NSCLC, several attempts 
have also been made to apply ICIs to perioperative 
treatments.
   Forde et al. reported the results of the first 
phase II trial conducted to evaluate the efficacy of 
preoperative nivolumab therapy for patients with 
resectable NSCLC64）. Twenty-one patients with 
stage I-IIIA resectable NSCLC were administered 2 
courses of preoperative nivolumab therapy every 2 
weeks. Of the 21 patients, 2 patients (10%) showed 
partial response, 18 (86%) showed stable disease, 
and 1 (5%) showed progressive disease. Of the 21 
patients, 20 underwent complete resection, and 
a major pathological response was obtained in 9 
patients (45%). Bott et al. reported the safety of 
surgery after preoperative nivolumab therapy65）. In 
this study, of 20 patients who underwent resection 
after 2 cycles of nivolumab, there was no operative 
mortality, while perioperative morbidity occurred in 
10 patients (50%). 
   These results suggest that preoperative ICI therapy 
may be safe and promising. At present, several trials 
are ongoing. Although the primary endpoint of some 
of these trials is the pathological response, survival 
data in comparison with those for the current 
standard strategies are eagerly awaited. 
CONCLUSION
   To date, much effort has been expended to 
establish effective perioperative treatments for 
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locally advanced NSCLC, and several treatments 
have come to be recognized as standard strategies. 
   For patients with completely resected stage II-III 
NSCLC, cisplatin plus vinorelbine is the standard 
adjuvant treatment based on several clinical trials. 
The prognosis has steadily improved, although no 
cure has yet been accomplished. Establishment of 
customized chemotherapy according to predictive 
biomarkers have been expected, whereas much 
effort would be necessary before applying in clinical 
practice.
   For cN2 disease, several strategies including 
adjuvant chemotherapy, induction chemotherapy, 
and induction chemoradiotherapy have been studied. 
However, with the development of ICI, the standard 
treatment for cN2 disease is being replaced by non-
surgical strategies. 
   On the other hand, another breakthrough 
is expected using new drugs as perioperative 
treatments. Postoperative EGFR-TKIs could provide 
favorable disease-free survival for patients with 
EGFR-mutant NSCLC. Similarly, many studies are 
ongoing to test the efficacy of ICIs as perioperative 
treatment for NSCLC (Table 2 and 3). We hope that 
with the evolution of treatment strategies, a cure is 
found in the near future for patients with resectable 
NSCLC.
Table 2.  Ongoing trials of induction therapy with immune checkpoint inhibitors
NCT number Phase Stage Neoadjuvant intervention Primary endpoint Target accrual
02259621 II IB-IIIA Nivolumab with or without ipilimumab MPR 30
02273375 III IB-IIIA Durvalumab vs placebo (BR31) DFS 1360
02486718 III IB-IIIA Atezolizumab vs BSC after platinum doublet (IMpower010) DFS 1280
02504372 III IB-IIIA Pembrolizumab vs placebo after platinum doublet(PEARLS) DFS 1080
02572843 II IIIA(N2) Cisplatin/docetaxel with durvalumab Event-free survival 68
02595944 III IB-IIIA Nivolumab vs BSC after platinum doublet(ALCHEMIST) DFS 903
02818920 II IB-IIIA Pembrolizumab (neoadjuvant and adjuvant)(TPO1501) Surgical feasibility 32
02927301 II IB-IIIA Atezolizumab (LCMC3) MPR 180
02998528 III IB-IIIA Nivolumab with ipilimumab vs nivolumab with platinum doublet vs platinum doublet (CheckMate816) MPR 624
03237377 II IIIA Durvalumab with radiation Safety 32
03425643 III II-IIIB(T3-4N2)
Pembrolizumab with platinum doublet vs platinum
doublet (KeyNote671) Event-free survival 786
03456063 III II-IIIB Atezolizumab with platinum doublet vs platinum doublet (IMpower030) MPR 374
03800134 III II-III Durvalumab with platinum doublet vs platinum doublet (AEGEAN) MPR 300
Abbreviations: BSC, best supportive care; MPR, major pathologic response; DFS, disease-free survival
Table 3.  Ongoing trials of adjuvant therapy with immune checkpoint inhibitors
NCT number Phase Stage Adjuvant intervention Primary endpoint Target accrual
02273375 III IB-IIIA Durvalumab vs placebo (BR31) DFS 1360
02486718 III IB-IIIA Atezolizumab vs BSC after platinum doublet (IMpower010) DFS 1280
02504372 III IB-IIIA Pembrolizumab vs placebo after platinum doublet (PEARLS) DFS 1080
02595944 III IB-IIIA Nivolumab vs BSC after platinum doublet(ALCHEMIST) DFS 903
Abbreviations: BSC, best supportive care; DFS, disease-free survival 
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